FIGURES

Figure 1A




Figure 1B




Figure 2



Frequency of TGFB1 positive cells
1.00
0.75
0.50
0.25
0.00
CRC
ESOPHAGEAL
GASTRIC
HNN
MELANOMA
NSCLC
OVARIAN
UROTHELIAL
Cancer type
TME
Tumor cell

Figure 3



CAF
CD8
CD4
Treg
exCD8
M1_TAM
M2_TAM
APCmye
Other
UROTHELIAL
OVARIAN
NSCLC
MELANOMA
HNN
GASTRIC
ESOPHAGEAL
CRC
Cancer type
Fraction cells
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

Figure 4



IDO1
PDL1
ARG1
TGFB1
Combination
UROTHELIAL
OVARIAN
NSCLC
*MELANOMA
HNN
GASTRIC
ESOPHAGEAL
CRC
Cancer type
0.25
0.20
0.15
0.10
0.05
0.00
Fraction cells

Figure 5



Pep12 – high homology
Pep11
Pep10
Pep09
Pep05
Pep04
Pep03
Pep02
Pep01
Pep08
Pep07
Pep06
TGFB1
TGFB2
TGFB3
Conservation

Figure 6



Pep01-1
Pep02-1
Pep05-1
Pep06-1
Pep09-1
Pep10-1
TNTC
Average IFNg ELISPOT spots per 1e5 cells (background subtracted)
Donor PBMC ID
0
200
400
600
D01
D02
D03
D04
D05
D06
D07
D08
D09
D10
D11
D12
D13
D14

Figure 6 (continued)




Figure 7A



TGFB1
TGFB2
TGFB3
Peptide
Pep01-1
Pep01-2
Pep01-3
Pep04-1
Pep04-2
Pep04-3
Pep05-1
Pep05-2
Pep05-3
Pep08-1
Pep08-2
Pep08-3
Pep09-1
Pep09-2
Pep09-3
Pep12-1
Pep12-2
Pep12-3
0
100
200
300
400
500
Average IFNg ELISPOT spots (background subtracted)

Figure 7B



Representative ELISPOT assays (triplicate)
Pep01
Pep04
Pep05
control
TGFB1
TGFB2
TGFB3
Pep09
Pep08
Pep12
control
TGFB1
TGFB2
TGFB3

Figure 8



Pep01-1
Pep01-2
Pep01-3
Pep04-1
Pep04-2
Pep04-3
Pep05-1
Pep05-2
Pep05-3
Average IFNg ELISPOT spots per 1e5 cells (background subtracted)
Donor PBMC ID
600
400
200
0
D08
D09
D11
D12
D13-1
D13-2
D16
D17
D05
D14

Figure 8 (continued)




Figure 9



Control
SLP1
SLP2
SLP1
SLP1_Ib
SLP1_IIa
SLP2
SLP2_Ia
SLP2_IIa
Control
0
200
400
600
800
Average IFNg Spots, Background Subtracted

Figure 10





A
Tumor weight (mg)
1500
1000
500
0
Control
SLP1
SLP2
B
%LAP of total live events
p = 0.07
25
20
15
10
5
0
Control
SLP1
SLP2
C
%CD4 out of total CD45+ events
*
15
10
5
0
Control
SLP1
SLP2
D
%CD8 out of total CD45+ events
20
15
10
5
0
Control
SLP1
SLP2

Figure 11





255 Cytotox study_255 cytotox_15 ns.fcs
Single Cells
8.79E5

Figure 11 (continued)

